Global Meloxicam Market

Meloxicam Comprehensive Study by Application (Hospitals, Clinics, Veterinary, Household), Form (Tablets, Injection), Sales Channel (Online, Offline) Players and Region - Global Market Outlook to 2030

Meloxicam Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Meloxicam
Meloxicam falls under the medication category of nonsteroidal anti-inflammatory drugs (NSAIDs), is mainly used to relieve pain, swelling, and inflammation in arthritis and rheumatoid arthritis. It works by stopping the production of chemical substances which cause pain and swelling. It is available in injection (liquid) and tablets forms generally used in hospitals, clinics, veterinary and household applications.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


Competition among existing players is due to the Meloxicam market share occupied by leading players. The industry leader is engaged in offering innovative and superior quality products to cater to the ever-growing demand for Meloxicam Market. The companies are implementing strategic activities such as acquisitions and mergers along with collaboration with companies in other industries to aid them in improving sustenance and maintaining their competitive advantage. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

LGM Pharma, LLC (United States), Lupin (India), Actavis Generics (United States), Cadila Pharmaceuticals (India), Apex HealthCare Ltd. (India), Sun Pharmaceutical Industries Limited (India), Zyla Life Science (United States), Baudax (United States) and Recro Pharma (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Axsome Therapeutics (United States), Iroko Pharma (United States) and Others.

Segmentation Overview
AMA Research has segmented the market of Global Meloxicam market by , Application (Hospitals, Clinics, Veterinary and Household) and Region.



On the basis of geography, the market of Meloxicam has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Form, the sub-segment i.e. Tablets will boost the Meloxicam market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Sales Channel, the sub-segment i.e. Online will boost the Meloxicam market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Rising Consumption of Meloxicam in Veterinary Applications

Market Growth Drivers:
Increasing Number of Arthritis Patients Across the Globe and Need for the Nonsteroidal Anti-inflammatory Drug in Various Applications

Challenges:
Stringent Regulatory Guidelines on Meloxicam

Restraints:
Side Effects Related Risks Associated with Meloxicam

Opportunities:
Growing Spendings on the Nonsteroidal Anti-inflammatory Drug will Boost the Meloxicam Market

Market Leaders and their expansionary development strategies
In January 2024, Heron Therapeutics, Inc., a commercial-stage biotechnology company, announced that the U.S. Food and Drug Administration (the "FDA") has approved its supplemental New Drug Application ("NDA") for ZYNRELEF (bupivacaine and meloxicam) extended-release solution to expand the indication for soft tissue and orthopedic surgical procedures including foot and ankle, and other procedures in which direct exposure to articular cartilage is avoided.
In December 2020, Lupin announced the launch of Meloxicam Capsules, 5 mg, and 10 mg, having received an approval from the United States Food and Drug Administration.
"FDA is aware that some veterinarians prescribe or use METACAM in an extra-label manner. When an approved drug is used in a manner other than what is stated on the label, it is an extra-label (or “off-label”) use. Under certain circumstances, veterinarians are allowed to use a drug in an extra-label manner. The boxed warning on the METACAM labels and generic meloxicam labels helps inform veterinarians of the serious risks associated with extra-label use of meloxicam in cats."

Key Target Audience
Meloxicam Manufacturers, Meloxicam International Traders, Meloxicam Distributors and Suppliers, Research and Development Institutes, Potential Investors, Regulatory Bodies and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Hospitals
  • Clinics
  • Veterinary
  • Household
By Form
  • Tablets
  • Injection

By Sales Channel
  • Online
  • Offline

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Arthritis Patients Across the Globe
      • 3.2.2. Need for the Nonsteroidal Anti-inflammatory Drug in Various Applications
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulatory Guidelines on Meloxicam
    • 3.4. Market Trends
      • 3.4.1. Rising Consumption of Meloxicam in Veterinary Applications
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Meloxicam, by Application, Form, Sales Channel and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Meloxicam (Value)
      • 5.2.1. Global Meloxicam by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Clinics
        • 5.2.1.3. Veterinary
        • 5.2.1.4. Household
      • 5.2.2. Global Meloxicam by: Form (Value)
        • 5.2.2.1. Tablets
        • 5.2.2.2. Injection
      • 5.2.3. Global Meloxicam by: Sales Channel (Value)
        • 5.2.3.1. Online
        • 5.2.3.2. Offline
      • 5.2.4. Global Meloxicam Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Meloxicam: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. LGM Pharma, LLC (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Lupin (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Actavis Generics (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Cadila Pharmaceuticals (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Apex HealthCare Ltd. (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sun Pharmaceutical Industries Limited (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Zyla Life Science (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Baudax (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Recro Pharma (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Meloxicam Sale, by Application, Form, Sales Channel and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Meloxicam (Value)
      • 7.2.1. Global Meloxicam by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Clinics
        • 7.2.1.3. Veterinary
        • 7.2.1.4. Household
      • 7.2.2. Global Meloxicam by: Form (Value)
        • 7.2.2.1. Tablets
        • 7.2.2.2. Injection
      • 7.2.3. Global Meloxicam by: Sales Channel (Value)
        • 7.2.3.1. Online
        • 7.2.3.2. Offline
      • 7.2.4. Global Meloxicam Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Meloxicam: by Application(USD Million)
  • Table 2. Meloxicam Hospitals , by Region USD Million (2018-2023)
  • Table 3. Meloxicam Clinics , by Region USD Million (2018-2023)
  • Table 4. Meloxicam Veterinary , by Region USD Million (2018-2023)
  • Table 5. Meloxicam Household , by Region USD Million (2018-2023)
  • Table 6. Meloxicam: by Form(USD Million)
  • Table 7. Meloxicam Tablets , by Region USD Million (2018-2023)
  • Table 8. Meloxicam Injection , by Region USD Million (2018-2023)
  • Table 9. Meloxicam: by Sales Channel(USD Million)
  • Table 10. Meloxicam Online , by Region USD Million (2018-2023)
  • Table 11. Meloxicam Offline , by Region USD Million (2018-2023)
  • Table 12. South America Meloxicam, by Country USD Million (2018-2023)
  • Table 13. South America Meloxicam, by Application USD Million (2018-2023)
  • Table 14. South America Meloxicam, by Form USD Million (2018-2023)
  • Table 15. South America Meloxicam, by Sales Channel USD Million (2018-2023)
  • Table 16. Brazil Meloxicam, by Application USD Million (2018-2023)
  • Table 17. Brazil Meloxicam, by Form USD Million (2018-2023)
  • Table 18. Brazil Meloxicam, by Sales Channel USD Million (2018-2023)
  • Table 19. Argentina Meloxicam, by Application USD Million (2018-2023)
  • Table 20. Argentina Meloxicam, by Form USD Million (2018-2023)
  • Table 21. Argentina Meloxicam, by Sales Channel USD Million (2018-2023)
  • Table 22. Rest of South America Meloxicam, by Application USD Million (2018-2023)
  • Table 23. Rest of South America Meloxicam, by Form USD Million (2018-2023)
  • Table 24. Rest of South America Meloxicam, by Sales Channel USD Million (2018-2023)
  • Table 25. Asia Pacific Meloxicam, by Country USD Million (2018-2023)
  • Table 26. Asia Pacific Meloxicam, by Application USD Million (2018-2023)
  • Table 27. Asia Pacific Meloxicam, by Form USD Million (2018-2023)
  • Table 28. Asia Pacific Meloxicam, by Sales Channel USD Million (2018-2023)
  • Table 29. China Meloxicam, by Application USD Million (2018-2023)
  • Table 30. China Meloxicam, by Form USD Million (2018-2023)
  • Table 31. China Meloxicam, by Sales Channel USD Million (2018-2023)
  • Table 32. Japan Meloxicam, by Application USD Million (2018-2023)
  • Table 33. Japan Meloxicam, by Form USD Million (2018-2023)
  • Table 34. Japan Meloxicam, by Sales Channel USD Million (2018-2023)
  • Table 35. India Meloxicam, by Application USD Million (2018-2023)
  • Table 36. India Meloxicam, by Form USD Million (2018-2023)
  • Table 37. India Meloxicam, by Sales Channel USD Million (2018-2023)
  • Table 38. South Korea Meloxicam, by Application USD Million (2018-2023)
  • Table 39. South Korea Meloxicam, by Form USD Million (2018-2023)
  • Table 40. South Korea Meloxicam, by Sales Channel USD Million (2018-2023)
  • Table 41. Taiwan Meloxicam, by Application USD Million (2018-2023)
  • Table 42. Taiwan Meloxicam, by Form USD Million (2018-2023)
  • Table 43. Taiwan Meloxicam, by Sales Channel USD Million (2018-2023)
  • Table 44. Australia Meloxicam, by Application USD Million (2018-2023)
  • Table 45. Australia Meloxicam, by Form USD Million (2018-2023)
  • Table 46. Australia Meloxicam, by Sales Channel USD Million (2018-2023)
  • Table 47. Rest of Asia-Pacific Meloxicam, by Application USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Meloxicam, by Form USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Meloxicam, by Sales Channel USD Million (2018-2023)
  • Table 50. Europe Meloxicam, by Country USD Million (2018-2023)
  • Table 51. Europe Meloxicam, by Application USD Million (2018-2023)
  • Table 52. Europe Meloxicam, by Form USD Million (2018-2023)
  • Table 53. Europe Meloxicam, by Sales Channel USD Million (2018-2023)
  • Table 54. Germany Meloxicam, by Application USD Million (2018-2023)
  • Table 55. Germany Meloxicam, by Form USD Million (2018-2023)
  • Table 56. Germany Meloxicam, by Sales Channel USD Million (2018-2023)
  • Table 57. France Meloxicam, by Application USD Million (2018-2023)
  • Table 58. France Meloxicam, by Form USD Million (2018-2023)
  • Table 59. France Meloxicam, by Sales Channel USD Million (2018-2023)
  • Table 60. Italy Meloxicam, by Application USD Million (2018-2023)
  • Table 61. Italy Meloxicam, by Form USD Million (2018-2023)
  • Table 62. Italy Meloxicam, by Sales Channel USD Million (2018-2023)
  • Table 63. United Kingdom Meloxicam, by Application USD Million (2018-2023)
  • Table 64. United Kingdom Meloxicam, by Form USD Million (2018-2023)
  • Table 65. United Kingdom Meloxicam, by Sales Channel USD Million (2018-2023)
  • Table 66. Netherlands Meloxicam, by Application USD Million (2018-2023)
  • Table 67. Netherlands Meloxicam, by Form USD Million (2018-2023)
  • Table 68. Netherlands Meloxicam, by Sales Channel USD Million (2018-2023)
  • Table 69. Rest of Europe Meloxicam, by Application USD Million (2018-2023)
  • Table 70. Rest of Europe Meloxicam, by Form USD Million (2018-2023)
  • Table 71. Rest of Europe Meloxicam, by Sales Channel USD Million (2018-2023)
  • Table 72. MEA Meloxicam, by Country USD Million (2018-2023)
  • Table 73. MEA Meloxicam, by Application USD Million (2018-2023)
  • Table 74. MEA Meloxicam, by Form USD Million (2018-2023)
  • Table 75. MEA Meloxicam, by Sales Channel USD Million (2018-2023)
  • Table 76. Middle East Meloxicam, by Application USD Million (2018-2023)
  • Table 77. Middle East Meloxicam, by Form USD Million (2018-2023)
  • Table 78. Middle East Meloxicam, by Sales Channel USD Million (2018-2023)
  • Table 79. Africa Meloxicam, by Application USD Million (2018-2023)
  • Table 80. Africa Meloxicam, by Form USD Million (2018-2023)
  • Table 81. Africa Meloxicam, by Sales Channel USD Million (2018-2023)
  • Table 82. North America Meloxicam, by Country USD Million (2018-2023)
  • Table 83. North America Meloxicam, by Application USD Million (2018-2023)
  • Table 84. North America Meloxicam, by Form USD Million (2018-2023)
  • Table 85. North America Meloxicam, by Sales Channel USD Million (2018-2023)
  • Table 86. United States Meloxicam, by Application USD Million (2018-2023)
  • Table 87. United States Meloxicam, by Form USD Million (2018-2023)
  • Table 88. United States Meloxicam, by Sales Channel USD Million (2018-2023)
  • Table 89. Canada Meloxicam, by Application USD Million (2018-2023)
  • Table 90. Canada Meloxicam, by Form USD Million (2018-2023)
  • Table 91. Canada Meloxicam, by Sales Channel USD Million (2018-2023)
  • Table 92. Mexico Meloxicam, by Application USD Million (2018-2023)
  • Table 93. Mexico Meloxicam, by Form USD Million (2018-2023)
  • Table 94. Mexico Meloxicam, by Sales Channel USD Million (2018-2023)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Meloxicam: by Application(USD Million)
  • Table 105. Meloxicam Hospitals , by Region USD Million (2025-2030)
  • Table 106. Meloxicam Clinics , by Region USD Million (2025-2030)
  • Table 107. Meloxicam Veterinary , by Region USD Million (2025-2030)
  • Table 108. Meloxicam Household , by Region USD Million (2025-2030)
  • Table 109. Meloxicam: by Form(USD Million)
  • Table 110. Meloxicam Tablets , by Region USD Million (2025-2030)
  • Table 111. Meloxicam Injection , by Region USD Million (2025-2030)
  • Table 112. Meloxicam: by Sales Channel(USD Million)
  • Table 113. Meloxicam Online , by Region USD Million (2025-2030)
  • Table 114. Meloxicam Offline , by Region USD Million (2025-2030)
  • Table 115. South America Meloxicam, by Country USD Million (2025-2030)
  • Table 116. South America Meloxicam, by Application USD Million (2025-2030)
  • Table 117. South America Meloxicam, by Form USD Million (2025-2030)
  • Table 118. South America Meloxicam, by Sales Channel USD Million (2025-2030)
  • Table 119. Brazil Meloxicam, by Application USD Million (2025-2030)
  • Table 120. Brazil Meloxicam, by Form USD Million (2025-2030)
  • Table 121. Brazil Meloxicam, by Sales Channel USD Million (2025-2030)
  • Table 122. Argentina Meloxicam, by Application USD Million (2025-2030)
  • Table 123. Argentina Meloxicam, by Form USD Million (2025-2030)
  • Table 124. Argentina Meloxicam, by Sales Channel USD Million (2025-2030)
  • Table 125. Rest of South America Meloxicam, by Application USD Million (2025-2030)
  • Table 126. Rest of South America Meloxicam, by Form USD Million (2025-2030)
  • Table 127. Rest of South America Meloxicam, by Sales Channel USD Million (2025-2030)
  • Table 128. Asia Pacific Meloxicam, by Country USD Million (2025-2030)
  • Table 129. Asia Pacific Meloxicam, by Application USD Million (2025-2030)
  • Table 130. Asia Pacific Meloxicam, by Form USD Million (2025-2030)
  • Table 131. Asia Pacific Meloxicam, by Sales Channel USD Million (2025-2030)
  • Table 132. China Meloxicam, by Application USD Million (2025-2030)
  • Table 133. China Meloxicam, by Form USD Million (2025-2030)
  • Table 134. China Meloxicam, by Sales Channel USD Million (2025-2030)
  • Table 135. Japan Meloxicam, by Application USD Million (2025-2030)
  • Table 136. Japan Meloxicam, by Form USD Million (2025-2030)
  • Table 137. Japan Meloxicam, by Sales Channel USD Million (2025-2030)
  • Table 138. India Meloxicam, by Application USD Million (2025-2030)
  • Table 139. India Meloxicam, by Form USD Million (2025-2030)
  • Table 140. India Meloxicam, by Sales Channel USD Million (2025-2030)
  • Table 141. South Korea Meloxicam, by Application USD Million (2025-2030)
  • Table 142. South Korea Meloxicam, by Form USD Million (2025-2030)
  • Table 143. South Korea Meloxicam, by Sales Channel USD Million (2025-2030)
  • Table 144. Taiwan Meloxicam, by Application USD Million (2025-2030)
  • Table 145. Taiwan Meloxicam, by Form USD Million (2025-2030)
  • Table 146. Taiwan Meloxicam, by Sales Channel USD Million (2025-2030)
  • Table 147. Australia Meloxicam, by Application USD Million (2025-2030)
  • Table 148. Australia Meloxicam, by Form USD Million (2025-2030)
  • Table 149. Australia Meloxicam, by Sales Channel USD Million (2025-2030)
  • Table 150. Rest of Asia-Pacific Meloxicam, by Application USD Million (2025-2030)
  • Table 151. Rest of Asia-Pacific Meloxicam, by Form USD Million (2025-2030)
  • Table 152. Rest of Asia-Pacific Meloxicam, by Sales Channel USD Million (2025-2030)
  • Table 153. Europe Meloxicam, by Country USD Million (2025-2030)
  • Table 154. Europe Meloxicam, by Application USD Million (2025-2030)
  • Table 155. Europe Meloxicam, by Form USD Million (2025-2030)
  • Table 156. Europe Meloxicam, by Sales Channel USD Million (2025-2030)
  • Table 157. Germany Meloxicam, by Application USD Million (2025-2030)
  • Table 158. Germany Meloxicam, by Form USD Million (2025-2030)
  • Table 159. Germany Meloxicam, by Sales Channel USD Million (2025-2030)
  • Table 160. France Meloxicam, by Application USD Million (2025-2030)
  • Table 161. France Meloxicam, by Form USD Million (2025-2030)
  • Table 162. France Meloxicam, by Sales Channel USD Million (2025-2030)
  • Table 163. Italy Meloxicam, by Application USD Million (2025-2030)
  • Table 164. Italy Meloxicam, by Form USD Million (2025-2030)
  • Table 165. Italy Meloxicam, by Sales Channel USD Million (2025-2030)
  • Table 166. United Kingdom Meloxicam, by Application USD Million (2025-2030)
  • Table 167. United Kingdom Meloxicam, by Form USD Million (2025-2030)
  • Table 168. United Kingdom Meloxicam, by Sales Channel USD Million (2025-2030)
  • Table 169. Netherlands Meloxicam, by Application USD Million (2025-2030)
  • Table 170. Netherlands Meloxicam, by Form USD Million (2025-2030)
  • Table 171. Netherlands Meloxicam, by Sales Channel USD Million (2025-2030)
  • Table 172. Rest of Europe Meloxicam, by Application USD Million (2025-2030)
  • Table 173. Rest of Europe Meloxicam, by Form USD Million (2025-2030)
  • Table 174. Rest of Europe Meloxicam, by Sales Channel USD Million (2025-2030)
  • Table 175. MEA Meloxicam, by Country USD Million (2025-2030)
  • Table 176. MEA Meloxicam, by Application USD Million (2025-2030)
  • Table 177. MEA Meloxicam, by Form USD Million (2025-2030)
  • Table 178. MEA Meloxicam, by Sales Channel USD Million (2025-2030)
  • Table 179. Middle East Meloxicam, by Application USD Million (2025-2030)
  • Table 180. Middle East Meloxicam, by Form USD Million (2025-2030)
  • Table 181. Middle East Meloxicam, by Sales Channel USD Million (2025-2030)
  • Table 182. Africa Meloxicam, by Application USD Million (2025-2030)
  • Table 183. Africa Meloxicam, by Form USD Million (2025-2030)
  • Table 184. Africa Meloxicam, by Sales Channel USD Million (2025-2030)
  • Table 185. North America Meloxicam, by Country USD Million (2025-2030)
  • Table 186. North America Meloxicam, by Application USD Million (2025-2030)
  • Table 187. North America Meloxicam, by Form USD Million (2025-2030)
  • Table 188. North America Meloxicam, by Sales Channel USD Million (2025-2030)
  • Table 189. United States Meloxicam, by Application USD Million (2025-2030)
  • Table 190. United States Meloxicam, by Form USD Million (2025-2030)
  • Table 191. United States Meloxicam, by Sales Channel USD Million (2025-2030)
  • Table 192. Canada Meloxicam, by Application USD Million (2025-2030)
  • Table 193. Canada Meloxicam, by Form USD Million (2025-2030)
  • Table 194. Canada Meloxicam, by Sales Channel USD Million (2025-2030)
  • Table 195. Mexico Meloxicam, by Application USD Million (2025-2030)
  • Table 196. Mexico Meloxicam, by Form USD Million (2025-2030)
  • Table 197. Mexico Meloxicam, by Sales Channel USD Million (2025-2030)
  • Table 198. Research Programs/Design for This Report
  • Table 199. Key Data Information from Secondary Sources
  • Table 200. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Meloxicam: by Application USD Million (2018-2023)
  • Figure 5. Global Meloxicam: by Form USD Million (2018-2023)
  • Figure 6. Global Meloxicam: by Sales Channel USD Million (2018-2023)
  • Figure 7. South America Meloxicam Share (%), by Country
  • Figure 8. Asia Pacific Meloxicam Share (%), by Country
  • Figure 9. Europe Meloxicam Share (%), by Country
  • Figure 10. MEA Meloxicam Share (%), by Country
  • Figure 11. North America Meloxicam Share (%), by Country
  • Figure 12. Global Meloxicam share by Players 2023 (%)
  • Figure 13. Global Meloxicam share by Players (Top 3) 2023(%)
  • Figure 14. Global Meloxicam share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. LGM Pharma, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 17. LGM Pharma, LLC (United States) Revenue: by Geography 2023
  • Figure 18. Lupin (India) Revenue, Net Income and Gross profit
  • Figure 19. Lupin (India) Revenue: by Geography 2023
  • Figure 20. Actavis Generics (United States) Revenue, Net Income and Gross profit
  • Figure 21. Actavis Generics (United States) Revenue: by Geography 2023
  • Figure 22. Cadila Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 23. Cadila Pharmaceuticals (India) Revenue: by Geography 2023
  • Figure 24. Apex HealthCare Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 25. Apex HealthCare Ltd. (India) Revenue: by Geography 2023
  • Figure 26. Sun Pharmaceutical Industries Limited (India) Revenue, Net Income and Gross profit
  • Figure 27. Sun Pharmaceutical Industries Limited (India) Revenue: by Geography 2023
  • Figure 28. Zyla Life Science (United States) Revenue, Net Income and Gross profit
  • Figure 29. Zyla Life Science (United States) Revenue: by Geography 2023
  • Figure 30. Baudax (United States) Revenue, Net Income and Gross profit
  • Figure 31. Baudax (United States) Revenue: by Geography 2023
  • Figure 32. Recro Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 33. Recro Pharma (United States) Revenue: by Geography 2023
  • Figure 34. Global Meloxicam: by Application USD Million (2025-2030)
  • Figure 35. Global Meloxicam: by Form USD Million (2025-2030)
  • Figure 36. Global Meloxicam: by Sales Channel USD Million (2025-2030)
  • Figure 37. South America Meloxicam Share (%), by Country
  • Figure 38. Asia Pacific Meloxicam Share (%), by Country
  • Figure 39. Europe Meloxicam Share (%), by Country
  • Figure 40. MEA Meloxicam Share (%), by Country
  • Figure 41. North America Meloxicam Share (%), by Country
List of companies from research coverage that are profiled in the study
  • LGM Pharma, LLC (United States)
  • Lupin (India)
  • Actavis Generics (United States)
  • Cadila Pharmaceuticals (India)
  • Apex HealthCare Ltd. (India)
  • Sun Pharmaceutical Industries Limited (India)
  • Zyla Life Science (United States)
  • Baudax (United States)
  • Recro Pharma (United States)
Additional players considered in the study are as follows:
Axsome Therapeutics (United States) , Iroko Pharma (United States) , Others
Select User Access Type

Key Highlights of Report


Apr 2024 214 Pages 71 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Meloxicam Market Quantitative research analysis
Global Meloxicam Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as LGM Pharma, LLC (United States), Lupin (India), Actavis Generics (United States), Cadila Pharmaceuticals (India), Apex HealthCare Ltd. (India), Sun Pharmaceutical Industries Limited (India), Zyla Life Science (United States), Baudax (United States) and Recro Pharma (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Rising Consumption of Meloxicam in Veterinary Applications" is seen as one of major influencing trends for Meloxicam Market during projected period 2023-2030.
The Meloxicam market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Meloxicam Market Report?

Have a Query? Click Here

Other Related Reports

Bile Acid Sequestrants Comprehensive Study by Type (Cholestyramine {Questran, Prevalite}, Colestipol {Colestid, Flavored Colestid}, Colesevelam {Welchol}), Application (Hospitals, Households, Clinics...
$ 3450
Enoxaparin API Comprehensive Study by Type (Enoxaparin API Powder, Enoxaparin API Injection), Application (Hospitals, Clinics, Others), Target Disease (Deep Vein Thrombosis, Pulmonary Embolism), Sale...
$ 3350
Knee Hyaluronic Acid Injections Comprehensive Study by Acid (Euflexxa, Hyalgan, Orthovisc, Monovisc, Supartz, Other), Sales Channel (Direct, Indirect), Dosage (Single Shot, Three-Five Shots), Solutio...
$ 3500
Venous Skin Ulcer Treatment Comprehensive Study by Type (Compression Therapy, Advanced Wound Dressings, Negative Pressure Wound Therapy, Skin Grafts & Substitutes, Medications, Others), Application (...
$ 3750
MET Inhibitor Drugs Comprehensive Study by Type (C-Met Biological Inhibitors, Small Molecule C-Met Inhibitors, C-Met Antagonist Antibodies, HGF Antagonist Antibodies, Kringle Variant Antagonists), Di...
$ 3650
Kennel Cough Treatment Comprehensive Study by Application (Mild Cases, Secondary Infection), Drug Type (Baytril, Doxycycline, Clavamox, Others), Route of Administration (Oral, Injectable, Intra-nasal...
$ 3450